307 related articles for article (PubMed ID: 26933988)
21. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe.
Stöver H; Meroueh F; Marco A; Keppler K; Saiz de la Hoya P; Littlewood R; Wright N; Nava F; Alam F; Walcher S; Somaini L
BMC Public Health; 2019 Jan; 19(1):30. PubMed ID: 30621658
[TBL] [Abstract][Full Text] [Related]
22. Prison health service directors' views on research priorities and organizational issues in conducting research in prison: outcomes of a national deliberative roundtable.
Simpson PL; Guthrie J; Butler T
Int J Prison Health; 2017 Jun; 13(2):113-123. PubMed ID: 28581378
[TBL] [Abstract][Full Text] [Related]
23. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
[TBL] [Abstract][Full Text] [Related]
24. Expert stakeholder perspectives on the acceptability of treatment-as-prevention in prison: a qualitative substudy of the 'Surveillance and Treatment of Prisoners with Hepatitis C' project (SToP-C).
Rance J; Lafferty L; Treloar C;
Addiction; 2021 Oct; 116(10):2761-2769. PubMed ID: 33751739
[TBL] [Abstract][Full Text] [Related]
25. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.
Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J;
J Viral Hepat; 2017 Sep; 24(9):733-741. PubMed ID: 28256027
[TBL] [Abstract][Full Text] [Related]
26. Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C;
J Viral Hepat; 2018 Dec; 25(12):1526-1532. PubMed ID: 30141261
[TBL] [Abstract][Full Text] [Related]
27. Violence and hepatitis C transmission in prison-A modified social ecological model.
Sazzad HMS; McCredie L; Treloar C; Lloyd AR; Lafferty L
PLoS One; 2020; 15(12):e0243106. PubMed ID: 33259565
[TBL] [Abstract][Full Text] [Related]
28. Tattooing in prisons--not such a pretty picture.
Hellard ME; Aitken CK; Hocking JS
Am J Infect Control; 2007 Sep; 35(7):477-80. PubMed ID: 17765561
[TBL] [Abstract][Full Text] [Related]
29. Use of telehealth to increase treatment access for prisoners with chronic hepatitis C.
Halder A; Li VG; Sebastian M; Nazareth S; Tuma R; Cheng W; Doyle A
Intern Med J; 2021 Aug; 51(8):1344-1347. PubMed ID: 34423535
[TBL] [Abstract][Full Text] [Related]
30. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.
Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C;
Int J Drug Policy; 2020 Mar; 77():102693. PubMed ID: 32045828
[TBL] [Abstract][Full Text] [Related]
31. A prospective study of hepatitis C incidence in Australian prisoners.
Luciani F; Bretaña NA; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR;
Addiction; 2014 Oct; 109(10):1695-706. PubMed ID: 24916002
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration.
Crowley D; Van Hout MC; Murphy C; Kelly E; Lambert JS; Cullen W
Health Justice; 2018 Dec; 6(1):23. PubMed ID: 30569249
[TBL] [Abstract][Full Text] [Related]
33. Surveillance and prevention of hepatitis C in Australian prisons.
Dolan K
Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):68-9. PubMed ID: 11833205
[TBL] [Abstract][Full Text] [Related]
34. Prison officers' views about hepatitis C testing and treatment: a qualitative enquiry.
Jack K; Islip N; Linsley P; Thomson B; Patterson A
J Clin Nurs; 2017 Jul; 26(13-14):1861-1868. PubMed ID: 27486922
[TBL] [Abstract][Full Text] [Related]
35. A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons.
Lafferty L; Wild TC; Rance J; Treloar C
Harm Reduct J; 2018 Aug; 15(1):39. PubMed ID: 30075728
[TBL] [Abstract][Full Text] [Related]
36. Detection, stratification and treatment of hepatitis C-positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison.
Connoley D; Francis-Graham S; Storer M; Ekeke N; Smith C; Macdonald D; Rosenberg W
J Viral Hepat; 2020 Oct; 27(10):987-995. PubMed ID: 32449969
[TBL] [Abstract][Full Text] [Related]
37. "That was quick, simple, and easy": Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison.
Lafferty L; Cochrane A; Sheehan Y; Treloar C; Grebely J; Lloyd AR
Int J Drug Policy; 2022 Jan; 99():103456. PubMed ID: 34560624
[TBL] [Abstract][Full Text] [Related]
38. Drug and alcohol use and treatment for Australian Indigenous and non-Indigenous prisoners: demand reduction strategies.
Dolan K; Rodas A; Bode A
Int J Prison Health; 2015; 11(1):30-8. PubMed ID: 25751705
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting.
Overton K; Clegg J; Pekin F; Wood J; McGrath C; Lloyd A; Post JJ
Int J Drug Policy; 2019 Oct; 72():123-128. PubMed ID: 30967329
[TBL] [Abstract][Full Text] [Related]
40. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine.
Morey S; Hamoodi A; Jones D; Young T; Thompson C; Dhuny J; Buchanan E; Miller C; Hewett M; Valappil M; Hunter E; McPherson S
J Viral Hepat; 2019 Jan; 26(1):101-108. PubMed ID: 30315691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
